Quantbot Technologies LP Spectrum Pharmaceuticals Inc Transaction History

Quantbot Technologies LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.7 - $1.4 $89 - $179	-128 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.63 - $1.59 $3,573 - $9,018	-5,672 Reduced 97.79%	128 $0
Q4 2021 Feb 11, 2022	BUY	$1.27 - $2.42 $7,366 - $14,036	5,800 New	5,800 $7,000
Q4 2020 Feb 12, 2021	SELL	$3.38 - $5.14 $36,142 - $54,962	-10,693 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.99 - $4.9 $15,228 - $24,955	5,093 Added 90.95%	10,693 $43,000
Q2 2020 Aug 13, 2020	BUY	$2.11 - $3.38 $11,605 - $18,590	5,500 Added 5500.0%	5,600 $18,000
Q1 2020 May 13, 2020	BUY	$1.83 - $3.45 $183 - $345	100 New	100 $0
Q4 2018 Feb 13, 2019	SELL	$6.39 - $16.99 $3,865 - $10,278	-605 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$16.52 - $24.82 $9,994 - $15,016	605 New	605 $10,000
Q2 2018 Aug 13, 2018	SELL	$14.31 - $21.75 $10,990 - $16,704	-768 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$16.09 - $23.07 $12,357 - $17,717	768 New	768 $12,000
Q4 2017 Feb 12, 2018	SELL	$13.36 - $20.73 $91,596 - $142,124	-6,856 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$8.75 - $14.07 $59,990 - $96,463	6,856	6,856 $96,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.